Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.002 | 0.1232 | 0.5 |
Brugia malayi | Latrophilin receptor protein 2 | 0.0017 | 0.0375 | 0.0375 |
Echinococcus granulosus | lamin dm0 | 0.0029 | 0.3537 | 1 |
Echinococcus multilocularis | lamin dm0 | 0.0029 | 0.3537 | 1 |
Echinococcus multilocularis | musashi | 0.0029 | 0.3537 | 1 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.002 | 0.1232 | 0.5 |
Trichomonas vaginalis | ap endonuclease, putative | 0.002 | 0.1232 | 0.5 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.002 | 0.1232 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0028 | 0.3397 | 0.3397 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.002 | 0.1232 | 0.5 |
Trichomonas vaginalis | ap endonuclease, putative | 0.002 | 0.1232 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.002 | 0.1232 | 0.5 |
Onchocerca volvulus | 0.0029 | 0.3537 | 0.5 | |
Onchocerca volvulus | 0.0029 | 0.3537 | 0.5 | |
Echinococcus granulosus | lamin | 0.0029 | 0.3537 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0029 | 0.3537 | 0.3537 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0053 | 1 | 1 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.002 | 0.1232 | 0.5 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0036 | 0.5545 | 0.5545 |
Echinococcus granulosus | intermediate filament protein | 0.0029 | 0.3537 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0036 | 0.5545 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0017 | 0.0375 | 0.0375 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.002 | 0.1232 | 0.5 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.002 | 0.1232 | 0.5 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0029 | 0.3537 | 0.3537 |
Brugia malayi | calcium-independent alpha-latrotoxin receptor 2, putative | 0.0017 | 0.0375 | 0.0375 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.002 | 0.1232 | 0.5 |
Echinococcus multilocularis | lamin | 0.0029 | 0.3537 | 1 |
Loa Loa (eye worm) | intermediate filament protein | 0.0029 | 0.3537 | 0.3537 |
Toxoplasma gondii | exonuclease III APE | 0.002 | 0.1232 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0053 | 1 | 1 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.002 | 0.1232 | 0.271 |
Schistosoma mansoni | lamin | 0.0029 | 0.3537 | 0.6116 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0053 | 1 | 1 |
Brugia malayi | intermediate filament protein | 0.0029 | 0.3537 | 0.3537 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.002 | 0.1232 | 0.271 |
Brugia malayi | exodeoxyribonuclease III family protein | 0.002 | 0.1232 | 0.1232 |
Schistosoma mansoni | ap endonuclease | 0.002 | 0.1232 | 0.1657 |
Schistosoma mansoni | lamin | 0.0029 | 0.3537 | 0.6116 |
Loa Loa (eye worm) | hypothetical protein | 0.0036 | 0.5545 | 0.5545 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.002 | 0.1232 | 0.5 |
Schistosoma mansoni | ap endonuclease | 0.002 | 0.1232 | 0.1657 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0029 | 0.3537 | 0.3537 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.002 | 0.1232 | 0.1232 |
Schistosoma mansoni | intermediate filament proteins | 0.0029 | 0.3537 | 0.6116 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.002 | 0.1232 | 0.5 |
Loa Loa (eye worm) | latrophilin receptor protein 2 | 0.0017 | 0.0375 | 0.0375 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.002 | 0.1232 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.